DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced the publication of data from the Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial. This trial evaluated ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome (FXS). The results of the trial have been published in a paper entitled, ‘A Phase 1/2, Open Label Assessment of the Safety, Tolerability, and Efficacy of Transdermal Cannabidiol (ZYN002) for the Treatment of Pediatric Fragile X Syndrome’ (Heussler, Helen; Cohen, Jonathan; Silove, Natalie, et al.) in the August 2nd online edition of Journal of Neurodevelopmental Disorders. These data were recently presented at the 2019 Annual Meeting of the American Psychiatric Association (APA).
This new publication can be accessed at the following link: https://rdcu.be/bMTnd.
“Fragile X is a family diagnosis, impacting
... read more at: https://mychesco.com/a/news/business/products/zynerba-pharmaceuticals-announces-publication-of-zygel-zyn002-12-week-open-label-fragile-x-syndrome-data-in-the-journal-of-neurodevelopmental-disorders/